超声测量心外膜脂肪厚度评价利拉鲁肽治疗肥胖型T2DM的疗效

目的 通过超声测量心外膜脂肪（EAT）厚度来评价利拉鲁肽治疗肥胖型2型糖尿病（T2DM）的疗效。方法 纳入36例肥胖T2DM患者，采取利拉鲁肽单一药物治疗。分别于治疗前和治疗3个月后应用超声测量患者的EAT厚度，同时测量体格指标和检测空腹血糖（FBG）、糖化血红蛋白（HbA1c）等生化指标。分析治疗前后EAT的变化与体格指标的变化之间是否相关。结果 患者的EAT厚度在治疗后明显降低（P<0.05）,并且EAT厚度变化与腰围（WC）、臀围（HC）及体质指数（BMI）变化存在正相关。 结论 可以通过超声测量EAT厚度评估利拉鲁肽治疗肥胖型T2DM的效果。

Effect of liraglutide on epicardial adipose tissue thickness measured by echocardiography in patients with obese type 2 diabetes mellitus

Aim To evaluate the effect in patients with obese T2DM treated with liraglutide, through measuring epicardial adipose tissue(EAT) thickness with echocardiography. Methods 36 patients with obese T2DM were included and treated with liraglutide monotheraphy. EAT thickness was measured with echocardiography, before treatment and after 3-month treatment, meanwhile anthropometric indictors and biochemical indictors(fasting blood-glucose, HbA1c, et al) were detected. The correlation between variation of EAT thickness and variation of anthropometric indicators was analyzed. Results EAT thickness was reduced significantly after treatment(P<0.05). Especially, the variation of EAT thickness had significantly positive correlation with the variation of waist circumference(WC), hip circumference(HC) and body mass index(BMI). Conclusions EAT as measured with echocardiography can assess the efficacy of liraglutide in patients with obese T2DM .